RejuverSen S.L.

RejuverSen SL (formerly Rejuveron Senescence Therapeutics) is a Swiss longevity biotech startup cofounded by Dr. Manuel Serrano and working to develop senolytic therapies against age-related disease,. Their lead program is or was intended to clear senescent cells that are created after chemotherapy by inhibiting the PD-L2 ligand to enable senescent cell destruction by the immune system.

While cells enter senescence as a defensive mechanism against cancer or as an early response to chemotherapy, if they are not cleared out early by the immune system they can promote further tumor growth and relapse through immune-suppressive effects and by remodeling the tissue in which the cancer is embedded. Dr. Serrano’s lab discovered that senescent tumor cells evade the immune system via the PD-L2 system, which inhibits T-cell activation amongst other effects. Their lead program, RST-001, targets senescent cells generated by and residual after triple-negative breast cancer, using a proprietary antibody that is currently in IND-enabling studies, and expect it to enter clinical research in 2025.

RST-002 was intended to treat chronic kidney disease and idiopathic pulmonary fibrosis (IPF), a terrible disease of aging characterized by lung scarring and a high burden of senescent cells. Per the company’s website, RST-002 has a “Strong anti-fibrotic effect demonstrated in fibrosis models, including IPF and CKD, supported by a novel and differentiated mechanism of action.” RST-003 is listed for unspecified fibrotic disease(s), with an icon suggesting liver cirrhosis..

The company inlicensed the intellectual property from Dr. Serrano’s previous startup, Senolytic Therapeutics. RejuverSen is a portfolio company of Centenara Labs (formerly Rejuveron Life Sciences AG).